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A B S T R A C T
Liposomes formulated from the 1,3-diamidophospholipid Pad-PC-Pad are shear-responsive and thus promising
nano-containers to specifically release a vasodilator at stenotic arteries. The recommended preclinical safety
tests for therapeutic liposomes of nanometer size include the in vitro assessment of complement activation and
the evaluation of the associated risk of complement activation-related pseudo-allergy (CARPA) in vivo. For this
reason, we measured complement activation by Pad-PC-Pad formulations in human and porcine sera, along with
the nanopharmaceutical-mediated cardiopulmonary responses in pigs. The evaluated formulations comprised of
Pad-PC-Pad liposomes, with and without polyethylene glycol on the surface of the liposomes, and nitroglycerin
as a model vasodilator. The nitroglycerin incorporation efficiency ranged from 25% to 50%. In human sera,
liposome formulations with 20 mg/mL phospholipid gave rise to complement activation, mainly via the alter-
native pathway, as reflected by the rises in SC5b-9 and Bb protein complex concentrations. Formulations having
a factor of ten lower phospholipid content did not result in measurable complement activation. The weak
complement activation induced by Pad-PC-Pad liposomal formulations was confirmed by the results obtained by
performing an in vivo study in a porcine model, where hemodynamic parameters were monitored continuously.
Our study suggests that, compared to FDA-approved liposomal drugs, Pad-PC-Pad exhibits less or similar risks of
CARPA.
1. Introduction
Over the last two decades, liposomal formulations, developed as
containers for the targeted and controlled release of drugs, have been
studied in detail [1–3]. Some of these drugs have been approved by the
Food and Drug Administration (FDA) [4]. Controlled drug release over
time in a stenotic artery due to specific liposome sensitivity on higher
local wall shear stress, can potentially increase the therapeutic index of
an encapsulated vasodilating drug [5]. Simultaneously, when the active
drug, protected by encapsulation, is circulating in the human body, side
effects observed after systemic administration are reduced as often
described for oncological therapeutics [6]. For cardiovascular
treatment agents, hypotension is a characteristic side effect which may
be observed when vasodilating drugs are systemically administered in
case of an acute ischemic event, in order to increase local perfusion
pressure in a suffering organ such as the heart, the brain, or the kidneys
[7].
The pathology of atherosclerosis is characterized by the narrowing
and hardening of blood vessels as a result of atherosclerotic plaque
formation [8]. This significant narrowing of the arterial blood vessels
alters blood flow and causes changes in the average wall shear stress in
comparison to physiological conditions [9]. It has been reported that an
80%-constricted artery gives rise to a wall shear stress increase of one
order of magnitude [10]. Such an increase of shear stress has been
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proposed as a trigger signal for targeted vasodilator delivery [5].
Nanometer-sized, lentil-shaped Pad-PC-Pad liposomes have shown the
unique property of being able to release their cargo under mechanical
stimuli [11]. Targeted drug delivery by these liposomes can be used to
mitigate systemic side effects caused by the intravenous administration
of vasodilators during cardiovascular emergencies. Based on these li-
posomes, we focus on the development of an infusion-based medication
to be given to the patient at any location, for example at the site of a
myocardial infarction. The medication should be active until the patient
reaches the operation theater. As continuous infusion, it should not stay
in the blood stream for prolonged residence time.
Nonetheless, liposomal drugs are often recognized as foreign par-
ticles and hence are attacked by the immune system leading to a bio-
chemical cascade termed complement activation[12]. If there is any
complement activation, it is helpful to understand the mechanism be-
hind the interaction of liposomes with the immune system. In the
serum, there are> 30 complement proteins which usually contribute
as defenders. Some of them can split into fragments when stimulated.
The complement protein cleavage (cf. Fig. 1) can be activated along
three pathways, termed classical, lectin, and alternative [13]. The main
differences among the three pathways are displayed in Fig. 1. In the
classical pathway, which is mainly mediated by an antigen-antibody
complex (star), the C1 complex (light blue-colored) initiates the acti-
vation of the C3 (light brown-colored) and C5 (orange-colored) proteins
by triggering the proteins C2 (pink-colored) and C4 (green-colored),
thereby giving rise to C3- and C5-convertases. In order to cleave the C5
protein, the immune system can also follow another route, namely the
lectin pathway, which is mediated by the interaction between mannose-
binding lectin (MBL) and the surface of a pathogen, leading to the
cleavage of the C3 and C5 proteins. Cleaved C5 links the proteins C6
(gray-colored), C7 (purple-colored), C8 (dark blue-colored), and the
polymeric C9 (red-colored), thereby producing the complex C5b-9,
known as the Membrane Attack Complex (MAC) or the Terminal Com-
plement Complex (TCC). The MAC induces the formation of a defect in
the cell membrane that damages or destroys the suspected
microorganism, and it can also form via the alternative pathway, due to
interaction with the C3 protein, the B-factor fragment Bb (yellow), and
the surface of a pathogen (hexagon). These interactions lead to the C5
protein and the MAC formation [14].
Released complement protein fragments such as C3a and C5a sti-
mulate mast cells, granulocytes and macrophages, which can sig-
nificantly contribute to cardiovascular distress [15–17]. The particle
morphology can play a decisive role in preventing phagocytosis pro-
cesses [18,19] like those ones mediated by pulmonary intravascular
macrophages as it has been recently discussed [20].
The activation of the immune system may lead to an adverse im-
mune phenomenon known as complement activation-related pseudo-al-
lergy (CARPA) [21]. CARPA is used to describe acute hypersensitivity
reactions (HSRs) to nanomedicines occurring in up to 45% of in-
dividuals [22]. In some individuals, these HSRs can be severe or even
fatal [23]. It has been proposed that pigs can provide a sensitive,
quantitative, and biologically relevant animal model of severe human
CARPA [24–28]. The main manifestation of CARPA is cardiopulmonary
distress, caused by pulmonary hypertension, which is critical for pa-
tients suffering from cardiac pathologies [23]. It leads to changes in
pulmonary arterial pressure (PAP) and systemic arterial pressure (SAP)
[26,29,30]. Due to this potential reactivity, the European Medicines
Agency recommends in vitro and in vivo assessments of CARPA as a
preclinical immune toxicity test in the development of liposomal drugs
[31]. Detection and prevention of CARPA at an early stage of nano-
medicine research is one of the strategies to successfully develop na-
nopharmaceutics. Liposomal drugs that cause CARPA have been re-
ported previously [21,32]. Phospholipid bilayers can activate the
complement system, and, among other factors, size, shape, lipid com-
position, and presence of surface charges are all sources for complement
activation by liposomes in vitro[15,23,24]. Therefore, one step on the
road to testing shear-responsive Pad-PC-Pad liposomes clinically is the
evaluation and minimization of their risk for HSRs.
In the present communication, we hypothesize that Pad-PC-Pad lipo-
somes, containing PEGylated lipids and nitroglycerin, hardly trigger CARPA.
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Fig. 1. Main steps of the complement activation cascade.
The identification of the SC5b-9 complex (light blue-co-
lored box) through the three pathways provides an insight
into understanding the interaction between Pad-PC-Pad
liposomes and the immune system. The classical pathway
(yellow-colored box) is mediated by an antigen-antibody
complex, whereas the lectin pathway (also a yellow-co-
lored box) and the alternative pathway (gray-colored box)
are initiated at the pathogen surfaces. (For interpretation
of the references to colour in this figure legend, the reader
is referred to the web version of this article.)
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We know that the activation of the complement system causes the
formation of the lytic C5b-9 complex bound to the S protein. The
concentration of the soluble C5b-9 (SC5b-9) protein complex was in-
vestigated in vitro, using an enzyme-linked immunosorbent assay
(ELISA). Herein, human or animal sera were incubated together with
the liposomal drug.
For the negative control, each donor's serum was treated with saline
(liposome buffer) or nitroglycerin (liposome payload). For the com-
parison with established liposomal drugs and the positive control, each
donor's serum was treated with Doxil, Abelcet, and zymosan. Doxil is
widely used in cancer treatment and consists of PEGylated liposomes
below 100 nm in size, encapsulating doxorubicin as the active drug
[33]. Abelcet is one of the three commercially available lipid for-
mulations containing amphotericin B, which is used to fight against
systemic fungal infections. It consists of ribbon-like complexes 1 to
10 μm in size [34]. Zymosan, a well-known complement activator, is a
bacterial glucan applied in experiments to quickly induce inflammation
and complement activation [35]. Samples containing the human sera
were subjected to SC5b-9 level detection. Furthermore, the three pos-
sible pathways, through which the MAC can be formed, were in-
vestigated individually through the detection of proteins within the
complement cascade including C4d (classical and lectin pathways) and
Bb (alternative pathway) protein concentrations. In porcine sera,
complement activation was evaluated via C3 protein consumption. In
vivo, the immune system response was investigated by intravenous in-
jection of liposomes into pigs with continuous monitoring of the he-
modynamic and hematological changes.
2. Materials and methods
2.1. Materials
A 0.1% commercially available nitroglycerin solution (Perlinganit,
UCB-Pharma AG, Bulle, Switzerland, and Nitroglycerin Bioren 0.1%,
Sintetica, Mendrisio, Switzerland) was used. PEGylated DSPE (DSPE-
PEG2000) was a gift from Lipoid (Ludwigshafen, Germany). Zymosan,
chloroform, and methanol were purchased from Merck p.a. (Darmstadt,
Germany) and Sigma-Aldrich Chemie GmbH (Buchs, Switzerland).
Doxil (Janssen-Cilag International NV, Beerse, Belgium) and Abelcet
(Teva Pharmaceutical Works Ltd.) were used as purchased. Saline so-
lution (0.9% NaCl, 308 mOsm/L) was purchased from Teva
Pharmaceutical Works Ltd. (Budapest, Hungary) and Bichsel AG
(Interlaken, Switzerland). All chemicals were of pharmaceutical grade
and used without further purification.
Human serum samples of healthy volunteers were obtained ac-
cording to the institutionally approved phlebotomy protocol at the
Semmelweis University (Budapest, Hungary). Porcine sera were pro-
vided by the Institute of Animal Breeding and Nutrition Research
Institute (Herceghalom, Hungary). All the sera were stored at a tem-
perature of −80 °C until use.
2.2. Lipid synthesis
Pad-PC-Pad (1,3-palmitoylamido-1,3-deoxy-sn-glycero-2-phosphati-
dylcholine) was prepared following the reported protocol [11,36].
Briefly, starting from 1,3-dichloropropan-2-ol, the protected phosphate
head group was introduced by using phosphoryl chloride, N-Boc-ami-
noethanol, and ammonium hydroxide. Subsequent treatment with so-
dium azide led to the substitution of both chlorides. A Staudinger-type
reduction of the resulting bis-azide yielded the free bis-amine.
Using a Schotten-Baumann-type protocol with palmitoyl chloride,
fatty acyl chains were introduced. Finally, the head group was de-
protected and quarternized, yielding Pad-PC-Pad. The product was
purified sequentially by silica gel column chromatography (silica
63–200, 60 Å, Chemie Brunschwig AG, Basel, Switzerland), using a
mixture of chloroform, methanol, and water (65:25:4 v/v/v), by pre-
cipitation in cold acetone, and by size exclusion chromatography on
Sephadex LH-20 (GE Healthcare Biosciences, Uppsala, Sweden), using a
mixture of chloroform, methanol, and water (65:25:4 v/v/v).
2.3. Liposome preparation
The phospholipids were dissolved in chloroform in molar ratios as
described in Table 1: L1 and L2 contained Pad-PC-Pad and DSPE-
PEG2000, while L3 was formulated from Pad-PC-Pad only. The three
liposomal formulations were prepared via the standard thin film
method [37,38], and they were either hydrated with saline solution, in
the case of L2, or passively loaded with commercially available ni-
troglycerin, in the cases of L1 and L3. Each suspension was prepared in
order to get a final lipid concentration of 20 mg/mL, the highest con-
centration achievable using the Pad-PC-Pad lipids. The suspensions
were freeze-thawed in a twelve-step series: Frozen in liquid nitrogen
and heated in a 60 °C water bath. In order to get a size distribution of
around 100 nm in diameter, each liposomal suspension was downsized
by multiple barrel extrusions using Liposofast LF-50 (Avestin Inc., Ot-
tawa, Canada) through track-edged polycarbonate filter membranes
(Whatman Nucleopore, Sigma-Aldrich, Buchs, Switzerland) of selected
pore sizes: 400 nm (five times), 200 nm (five times), and 100 nm (15
times). The non-encapsulated nitroglycerin in the L1 and L3 suspen-
sions was removed by buffer exchange, using PD-10 desalting columns
with 5000 Da size exclusion limit, following the manufacturer's gravity
protocol (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). In the in
vitro experiments, the ten-fold diluted counterparts of L1, L2, and L3
were tested and labeled ‘L1a’, ‘L2a’, and ‘L3a’, respectively. The dilution
was carried out using saline solution.
For the in vivo experiment, three batches of liposomes, labeled L1′,
L2′, and L3′, were prepared using the same lipid composition as L1, L2,
and L3, respectively (cf. Table 1), and by following the protocol de-
scribed above. For the samples L1′ and L3′, Perlinganit was used as a
drug, whereas the sample L2′ comprised drug-free liposomes. Lipid
content was obtained by the phosphate test 2.0 [39]: 12 mg/mL for L1′,
16 mg/mL for L2′, and 11 mg/mL for L3′. All the liposomal suspensions
were stored at room temperature until use.
2.4. Liposome characterization
Lipid content in the liposomal suspension was determined after
purification by phosphate test 2.0 [39]. Briefly, liposome concentration
was calculated from the measured phosphate content (phosphate
moiety in the head group of the phospholipids): An aliquot (20 μL) of
the liposome suspension was diluted with ultrapure water (180 μL,
18.2 MΩcm) in a 0.5 to 2 mL microwave vial (Biotage, Stockholm,
Sweden). Then, 500 μL of a mixture (3/1 v/v) of nitric acid (65% Reag.
ISO, Reg. Ph. Eur. grade, Honeywell, Morristown, USA) and sulfuric
acid (95% Reag. ISO, Reg. Ph. Eur. grade, Honeywell, Morristown,
USA) was added. The vial was sealed and heated in a microwave to a
temperature of 180 °C for a period of 20 min (Biotage Initiator,
Table 1
Liposomal suspensions tested in vitro and in vivo.
Label Lipid composition (molar %) Load
In vitro In vivo Pad-PC-Pad DSPE-PEG2000
L1, L1aa L1′ 95 5 Nitroglycerin
L2, L2aa L2′ 95 5 Bare
L3, L3aa L3′ 100 – Nitroglycerin
a Liposomal suspension diluted ten times using saline solution.
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Stockholm, Sweden). The vial was allowed to cool down and the fol-
lowing solutions were added in sequence: Water (2.3 mL), ammonium
metavanadate and ammonium heptamolybdate coloring agent (1 mL),
and sodium hydroxide solution (10 M, 1 mL). The solution was allowed
to rest for ten minutes. The solution was then pipetted into a 96-well
plate (Nunc-Immuno plate F96 Polysorb, Roskilde, Denmark), using a
multi-channel pipette (eight times 300 μL), and the absorbance was
measured at a wavelength of 405 nm, using a plate reader (MultiskanFC
96 from Thermo Scientific, Waltham, USA).
Furthermore, the size of the liposomes, including the polydispersity
index (PDI), was obtained by dynamic light scattering (DLS), using a
Delsa Nano C (Beckman Coulter, Brea, USA). DLS measurements were
performed at a temperature of 25 °C, using two laser diodes working at
a wavelength of 658 nm. The scattering angle was set to 165 degrees.
The zeta (ζ) potential of the liposomal formulations was determined
by laser Doppler micro-electrophoresis, using a Zetasizer Nano-ZS
(Malvern Instruments Ltd., Malvern, UK). The measurements were
carried out at a temperature of 25 °C, using a wavelength of 633 nm.
The scattering angle was set to 173 degrees, using non-invasive back-
scattered (NIBS) optics. The experimental data were treated according
to the Smoluchowski equation.
The suspensions were diluted 30 times with saline prior to both DLS
and ζ potential measurements.
Transmission electron microscopy (TEM) images of the three lipid
formulations were obtained at cryogenic temperatures. Prior to the
measurements, the three liposomal suspensions were diluted to a con-
centration of 5 mg/mL and were mounted on glow-discharged holey
carbon grids, quickly frozen by a Cryoplunge CP3 system (Gatan Inc.,
Pleasanton, USA), and transferred to a JEM2200FS transmission elec-
tron microscope (JEOL Ltd., Tokyo, Japan) using a Gatan626 cryo-
holder. Cryo-electron micrographs were recorded at an acceleration
voltage of 200 kV at a magnification of 20,000, 4 to 8 μm under-focus,
and a dose of 10 electrons/Å2, using a F416 CMOS detector (TVIPS
GmbH, Gauting, Germany).
The morphology of the liposomes exhibits deviations from the
spherical shape towards ellipsoids, depending on the lipid composition.
The local curvature C and the eccentricity ε of the liposomes were es-
timated from the cryo-TEM projections (cf. Fig. 2). Therefore, ellipses
have been employed with a and b the major and minor semi-axes. The
curvature of an ellipse can be written as C = a b / (a2 sin2 (t) + b2 cos2
(t))3/2 being t the angle between a and a generic point lying on the
ellipse. For sphere-like liposome a= b = r, the curvature is given by
Ccircle = 1/r, being r the outer radius of the fitted circle. In case of an
elliptically shaped liposome, the local curvature Cellipse ranges from b/
a2 to a/b2. The eccentricity of an ellipse is given by = −ε b a1 2 2 and
ranges as 0 < ε < 1; for circles it is zero.
The efficiency of nitroglycerin loading was estimated indirectly
from the glucose content of the nitroglycerin solution measured by
electrospray ionization mass spectrometry (ESI-MS) using a Bruker
Daltonics esquire HCT ion trap mass spectrometry [40]. Here, a volume
of 0.1 mL of each sample was diluted ten times with methanol and
treated with 10 μL of trifluoroacetic acid. The ESI spectra were mea-
sured in the negative mode. The ESI-MS signal of the observed glucose-
trifluoroacetic acid adduct at 292.92 amu was compared to the ESI-MS
signal which an equally treated solution of nitroglycerin (Bioren 0.1%
containing 1 mg/mL nitroglycerin as active pharmaceutical ingredient
and 49 mg/mL glucose as excipient) yields. It was assumed that the
ratio of glucose versus nitroglycerin, as found in the commercial ni-
troglycerin solution, stays constant during the liposome formulation
and purification steps.
2.5. In vitro immunoassay in human sera via SC5b-9
Human sera from six donors were aliquoted and stored in Eppendorf
tubes at a temperature of −80 °C. Prior to use, they were thawed to
4 °C and kept in an ice bath. Each human serum was mixed with the
three liposomal suspensions (L1, L2, and L3) and their ten-times diluted
counterparts (L1a, L2a, L3a). Each serum was treated with saline and
nitroglycerin solution being the negative controls. For the comparison
with FDA-approved liposomal drugs and as positive control, mixtures of
each serum with Doxil (2 mg/mL doxorubicin, 12.7 mg/mL phospho-
lipids), Abelcet (5 mg/mL amphotericin B, 4.9 mg/mL phospholipids),
and zymosan (1.5 mg/mL) were used. Each mixture was incubated at a
temperature of 37 °C. The reaction was terminated after 5, 10, 20 and
40 min by adding 10 mM ethylenediaminetetraacetic acid (EDTA,
Sigma-Aldrich Kft, Budapest, Hungary). The level of SC5b-9 was
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Fig. 2. Structure of the two phospholipids used for the liposome preparations: Pad-PC-Pad (1) and DSPE-PEG2000 (2). Cryo-TEM micrographs of L1 Pad-PC-Pad/DSPE-PEG2000/
nitroglycerin (left), L2 Pad-PC-Pad/DSPE-PEG2000/saline (middle), and L3 Pad-PC-Pad/nitroglycerin (right) liposomes. The pure Pad-PC-Pad liposomal suspension contains many
aggregated clusters, possibly because the stiff membranes lack repulsive undulation movement. The curvature C of the liposomes was estimated: (51 nm)−1 to (44 nm)−1 for L1,
(130 nm)−1 to (10 nm)−1 for L2, and (100 nm)−1 to (5 nm)−1 for L3.
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quantified by a MicroVue SC5b-9 Plus ELISA kit (Quidel, San Diego,
USA). The assay was carried out following the manufacturer's protocol.
Classical and alternative pathways were tested using the MicroVue C4d
Plus ELISA and MicroVue Bb Plus ELISA kits (Quidel, San Diego, USA),
to detect the concentration of C4d and of Bb, respectively. The samples
prepared for SC5b-9, C4d, and Bb assays were diluted 20 times using
the specimen diluent provided by the SC5b-9 kit and additional 10 mM
EDTA, as the minimum dilution required to detect the optical density.
The lectin pathway was investigated using samples treated as described
above and supplemented with EGTA/Mg2+ (Ca2+ chelation), in order
to block selectively the classical pathway [41]. In this case, the Mi-
croVue C4d Plus ELISA assay was used to detect C4d concentration.
After termination of the reaction, the samples were diluted 30 times
with the specimen diluent provided by the C4d kit and additional
10 mM EDTA. Each sample was subjected to a further dilution step
before transferring it to the ELISA plate. The optical density was mea-
sured with a 96-well plate reader (FLUOstar Omega, BMG Labtech,
Ortenberg, Germany) at a wavelength of 450 nm (in the cases of SC5b-9
and Bb) and at a wavelength 405 nm (in the case of C4d).
2.6. SC5b-9 detection in porcine sera via C3 consumption
In a previous study [42], we tested complement activation in por-
cine samples, using the MicroVue Pan-Specific C3 Reagent Kit (Quidel,
San Diego, USA). This test, however, is rather qualitative for a study
involving porcine sera, because validity has only been demonstrated for
human sera. Therefore, we searched for an alternative kit to measure
directly the concentration of the SC5b-9 complex in porcine sera. We
identified the ELISA kits from MyBioSource Inc. (San Diego, USA) as
being possibly suited to this purpose. The manufacturer states that the
kit is a quantitative sandwich ELISA assay, to be used for determining
the level of SC5b-9 in undiluted original porcine body fluids. Following
the guidelines of the manufacturer concerning sample preparation and
the assay procedure, we did not find any significant difference between
the negative (phosphate-buffered saline) and positive (zymosan) con-
trols. As there was no support available from the supplier, we have to
state that the kit was inappropriate for our study. Thereafter, we
decided to investigate the level of SC5b-9 in porcine sera through the
qualitative detection of C3 consumption, using a MicroVue Pan-Specific
C3 Reagent Kit from Quidel Corp., which, to the best of our knowledge,
is the only possibility currently available on market.
Each donor's serum was treated with the liposomes, the positive and
negative controls as done with the human ones, see description in
Section 2.5. As stated above, complement activation in porcine samples
was assessed using the Quidel MicroVue Pan-specific C3 reagent kit.
This kit allowed for converting the C3 activity in animal samples to the
human SC5b-9 protein complex, which could be detected using the
SC5b-9 Plus ELISA kit. The optical density was measured with a 96-well
plate reader (FLUOstar Omega, BMG Labtech, Ortenberg, Germany) at a
wavelength of 450 nm.
2.7. Statistical analysis
The statistical analysis was carried out using GraphPad Prism 6
(GraphPad Software Inc., San Diego, USA). All samples, except those
incubated with zymosan, were compared with saline after 40 min of
incubation, using ordinary one-way ANOVA, followed by Dunnett's
multiple comparison test. P-values lower than 0.05 were considered as
statistically significant.
2.8. CARPA in the porcine model
Six domestic male, mixed breed Yorkshire-Hungarian landrace pigs,
weighing from 19 to 24 kg, were treated according to the protocol
approved by the local Animal Subject Review Committees. Animals
were pre-anesthetized intramuscularly with Calypsol/Xilazine 2–3/
1.5–2 mL/kg injections in the stalls, to avoid stress, and further an-
esthesia was maintained with 2 to 3% isoflurane in O2. Intubation was
performed with endotracheal tubes to maintain open airways and to
enable controlled ventilation. Spontaneous ventilation was followed by
a pulse-oximeter fixed on the tail to monitor oxygen saturation.
Temperature was measured rectally and monitored by an Innocare-P
anesthesia monitor. A capnograph was connected to the tracheal tube to
monitor end tidal CO2 and respiratory rate (CAP10 Medlab,
Medizinische Diagnosegeräte GmbH, Karlsruhe, Germany). Surgery was
done after povidone iodine (10%) sterilization of the skin. In order to
measure the PAP, a Swan-Ganz catheter (AI-07124, 5 Fr. 110 cm, Arrow
International Inc., Reading, USA) was introduced into the pulmonary
artery via the right external jugular vein, while the SAP was measured
in the femoral artery. Blood samples were taken from the left femoral
vein, before and after the injection of liposomes (time points after 1, 3,
5, 10, 20, and 30 min), and were collected in hirudin- and K2-EDTA
tubes. Liposome suspensions and zymosan were injected into the ani-
mals as bolus within a period of< 10 s via the left external jugular
vein. Hemodynamic changes (PAP, SAP, and heart rate (HR)) were
continuously monitored and either expressed in absolute or in relative
terms compared to the baseline throughout this study.
3. Results
3.1. Liposome characterization
The total lipid concentration was measured after purification and
found to be (20.40 ± 0.16) mg/mL for L1, (16.52 ± 0.10) mg/mL for
L2, and (18.72 ± 0.03) mg/mL for L3. Table 2 lists the related DLS and
ζ potential results. Within the estimated errors, the results for the li-
posomes with and without PEGylated lipids were comparable. The
measured eccentricity ε of the three liposomal formulations ranged
from zero to 0.95 (Table 2); the curvature C was estimated (Fig. 2,
caption). Preliminary data of the nitroglycerin incorporation efficiency
measured by ESI-MS showed 49% for L1 and 27% for L3. These results
indicated a beneficial effect of the presence of PEG network for re-
taining nitroglycerin inside a liposome.
Fig. 2 displays cryo-TEM images representing the morphology of the
liposomes. Pure Pad-PC-Pad liposomes formed aggregates (Fig. 2,
right), probably due to limited membrane flexibility. Membrane un-
dulation typically contributes to liposome-liposome repulsive forces
[43], but this aggregation of Pad-PC-Pad liposomes can be prevented by
adding a steric barrier in the form of 5% PEGylated lipids, as indicated
in the other two cryo-TEM images (Fig. 2, left and middle). Cryo-TEM
data further indicated that the liposome suspensions, containing the
PEGylated lipids, were less faceted compared to the liposomes made
Table 2
Characteristics of the liposomal formulations tested in vitro.
Label Lipid composition Lipid content
(mg/mL)
Mean diameter
(nm)
PDI Eccentricity ζ potential
(mV)
εmin εmax
L1 Pad-PC-Pad/DSPE-PEG2000 (nitroglycerin) 20.40 ± 0.16 122 ± 2 0.09 ± 0.01 0 0 −0.78 ± 0.18
L2 Pad-PC-Pad/DSPE-PEG2000 (bare) 16.52 ± 0.10 151 ± 2 0.21 ± 0.03 0.40 ± 0.01 0.91 ± 0.01 −1.78 ± 0.14
L3 Pad-PC-Pad (nitroglycerin) 18.72 ± 0.03 166 ± 9 0.19 ± 0.03 0.47 ± 0.01 0.95 ± 0.01 −0.60 ± 0.15
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from pure Pad-PC-Pad, and the addition of nitroglycerin reduced the
faceting of the liposomes, cf. Fig. 2. The diameters of liposomes derived
from the cryo-TEM images were in agreement with those from the DLS
data.
3.2. In vitro immunoassay in human sera
Fig. 3 shows the concentration of the protein C4d, without (A) and
with (B) the addition of EGTA/Mg2+, Bb (C), and the terminal complex
SC5b-9 (D) tested in human sera from six donors. The sera were in-
cubated with the liposomes or the appropriate controls for a period of
40 min. As the experimentally found lipid contents of the three lipo-
somal formulations corresponded to (20.40 ± 0.16) mg/mL for L1,
(16.52 ± 0.10) mg/mL for L2, and (18.72 ± 0.03) mg/mL for L3, the
obtained data were adjusted to the liposome concentration of 20 mg/
mL, in order to mitigate the effect of the lipid concentration on the
complement protein levels. Thus, the data were multiplied by the factor
0.98 for L1, 1.21 for L2, and 1.07 for L3. The phosphate test and the
DLS results enabled us to estimate the average liposome-entrapped
volume, which was 61.7 μL per mL suspension for L1 and 91.4 μL per
mL suspension for L3. According to the ESI-MS results, being the en-
capsulation efficiency 49% for L1 and 27% for L3, the total amount of
nitroglycerin per mL suspension was 30.4 μg for L1 and 24.6 μg for L3.
The diagrams in Fig. 3A and B provide the results of the classical
and lectin pathways, respectively. For the lectin pathway, the C4d level
of the sample containing Abelcet was not available. The C4d con-
centration of the samples did not show any significant difference
compared to saline. The only exception was zymosan, where a slight
increase in C4d concentration was observed, as illustrated in the dia-
gram of Fig. 3A.
Bb concentrations, see Fig. 3C, in the samples containing Abelcet
and zymosan increased four- and eight-fold with respect to saline. For
the liposomal suspensions L1 and L2, Bb concentration was found
comparable to Doxil and more than twice that of saline. Liposome
suspensions at a lower phospholipid content (L1a, L2a, and L3a), as
well as L3, did not show any significant increase in Bb level with respect
to saline.
The three pathways can lead to the formation of the terminal
complement complex detected by soluble C5b-9 concentration in the
serum. Fig. 3D displays the results with respect to the SC5b-9 con-
centration. It was found that zymosan activated the formation of the
SC5b-9 complex within only five minutes of incubation, cf. Supple-
mentary information, Fig. S1, and increased up to 80 times after 40 min
of incubation as compared to saline. Abelcet increased SC5b-9 con-
centration> 15 times compared to saline. SC5b-9 concentration in the
liposomal suspensions L2 and L3 increased five-fold compared to Doxil
and ten-fold compared to the negative control, whereas L1 showed
more than seven times and 15 times higher SC5b-9 levels compared to
saline and Doxil, respectively. At a lower phospholipid concentration,
i.e. L1a, L2a, and L3a, the level of SC5b-9 increased less than twice the
amount of saline and, within the standard deviation, the results were
comparable to Doxil.
The controls and the liposomes were also incubated with each
human serum for 5, 10, and 20 min. These data at the selected time
points show a trend summarized in Supplementary information, Fig. S1.
3.3. Validation of the in vitro human sera study
The results of the in vitro study using human sera were underpinned
by the in vitro assessment of complement activation with porcine sera
from six animals, and the in vivo experiment with continuous mon-
itoring of the hemodynamic behavior of six Yorkshire pigs after the
injection of Pad-PC-Pad liposomes.
3.3.1. In vitro immunoassay in porcine sera
The level of complement activation in porcine sera from six animals,
tested through C3 consumption, is displayed in Fig. 4. The sample
containing saline was used as a baseline. The level of C3 consumption in
Abelcet increased up to 72% over the baseline and was twice that of
zymosan. Doxil led up to a 20% increase, showing similar complement
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Fig. 3. The level of C4d (A), of C4d supplemented by
EGTA/Mg2+ (B), of Bb (C), and of SC5b-9 (D) from human
sera of six donors incubated for a period of 40 min at a
temperature of 37 °C with saline, nitroglycerin (NTG), li-
posomes containing low (L1a, L2a, L3a) and high (L1, L2,
L3) lipid contents, Doxil, Abelcet, and zymosan. The data
are presented as mean values, including error bars derived
from the standard deviation among the sera. Each symbol
(triangle, square, circle, star, cross, rhombus) represents
data from one of the six donors. The values were adjusted
to the liposome concentrations of 2 and 20 mg/mL, re-
spectively. For the statistical analysis, zymosan was ex-
cluded.
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activity as in L1 and L2 with 22% and 20% rises over saline, respec-
tively. Lower levels of C3 consumption were found for L3 and L3a - an
increase of< 10% – and even less for L1a and L2a with increases over
the baseline of 4% and 3%, respectively. According to the statistics,
significant differences with respect to saline were only found for the
undiluted sample containing Pad-PC-Pad/DSPE-PEG2000 loaded with
nitroglycerin (L1) and for Abelcet.
3.3.2. In vivo study in the porcine model
Six pigs were used to explore in each the hemodynamic changes
caused by sequential intravenous administrations of selected liposome
boluses, as specified in Tables 3 and 4. L1′ was tested in three doses. L2′
and L3′ were injected using a pre-defined dose in the six animals. At the
end of each experiment, zymosan was injected as positive control. The
sequences, with which the liposomal formulations were injected, are
represented in Supplementary information, see Table S2.
The human therapeutic dose (HTD) of intravenous nitroglycerin so-
lution ranges from 13 to 133 μg in one minute [44,45]. The liposome
doses were adjusted in order to obtain 0.5 mg Pad-PC-Pad per kg of pig
and flushed into the circulation with 5 mL saline solution. Therefore, the
total amounts of phospholipids for the samples containing PEGylated
lipids (L1′, L2′) were 0.6 mg/kg (0.5 mg/kg Pad-PC-Pad plus 0.1 mg/kg
DSPE-PEG2000) for HTD. Using the same lipid formulation as in L1′,
another two nitroglycerin dosages were prepared: 0.33 × HTD and
3 × HTD with a total concentration of 0.2 mg/kg (0.17 mg/kg Pad-PC-
Pad plus 0.03 mg/kg DSPE-PEG2000) and 1.8 mg/kg (1.5 mg/kg Pad-
PC-Pad plus 0.3 mg/kg DSPE-PEG2000), respectively. According to ESI-
MS measurements the dose of nitroglycerin was 94 μg per minute for L1′
and 79 μg per minute for L3′, in agreement with the HTD. As the injec-
tion time of the liposomal suspension was about 10 s, the nitroglycerin
payload was 0.8 μg per kg pig for L1′ and 0.7 μg per kg pig for L3′.
As expected, the injection of liposomal drugs led to HR modifica-
tion, a PAP increase, and a change of SAP. In one of the six pigs, the L1′
injection led to a slight increase of HR, which returned to baseline level
within minutes. All other samples did not cause any visible change of
the HR, besides the gradual, slow increase of the HR during the course
of the experiment, owing to anesthesia. Moreover, no cardiac ar-
rhythmia in the form of tachycardia or bradycardia, or extrasystoles,
was observed.
Changes in PAP and SAP observed upon injecting the liposomes
were calculated as relative changes in percentage terms of the baseline
value at pre-injection time. An overview of the recorded PAP, SAP, and
HR graphs upon injection of Perlinganit-loaded and drug-free liposomes
is represented in the Supplementary information, see Figs. S2 to S7.
The zymosan injection always led to an immediate PAP increase of
up to 180%. The injection of 70 μg nitroglycerin, however, caused a
decrease in the PAP of maximal 25%. These results set the stage for
assessing the CARPA caused by the liposomal suspensions.
The measured maximal changes in PAP upon injecting the corre-
sponding liposomal formulations are listed in Table 3. In all cases,
sample L1′ with 1.5 mg/kg of Pad-PC-Pad showed an increase of the
PAP of up to 76%, thus indicating mild complement activation. This
increase is similar to the hemodynamic changes that occurred following
an injection of Doxebo liposomes [25]. Compared to other liposomal
drugs, such as Ambisome, where the PAP increases by 200% for an
injection of 0.01 mg/kg [27], or Doxil, with an increase up to 400% of
the baseline [25] for 0.06 mg/kg phospholipid, the observed increase in
PAP with liposomes encapsulating nitroglycerin also had a minimal
effect of about a 33% increase in PAP, most likely caused by the ag-
gregation of liposomes [42]. Furthermore, it should be noted that it is
only the response to the first injection where cumulative effects can be
excluded. In fact, self-induced tolerance, i.e., tachyphylaxis has been
known in case of certain liposomes. However, the fact that we saw
reactions to the second and third boluses of L1′ argued against full ta-
chyphylaxis after the first injection, enabling us to test L2′ and L3′ at the
same doses as L1′ was first injected (0.5 mg/kg). The presence of very
similar, small reactions to L2′ and L3′ cannot be explained by tachy-
phylaxis, as tachyphylaxis prevents follow-up reactions to identical
doses, and L1′ was applied three times at much higher doses, which
would fully eliminate any further reaction in the presence of tachy-
phylaxis. Partial tachyphylaxis cannot be ruled out, but overall, these
pig data showed very mild changes, which are most likely biologically
irrelevant. However, the mere presence of even small hemodynamic
changes point to a risk of CARPA in case of substantial overdosing of
test liposomes.
3.3.3. Tachyphylaxis in pigs after Pad-PC-Pad injection
PAP usually increased after the first liposome injection. The reaction
to a subsequent injection showed possible tachyphylaxis. An example of
the PAP response is represented in Fig. 5 regarding the injection re-
gimes, with the injection sequence being modified for samples L1′
through L3′. The upper panel on Fig. 5 displays PAP changes in a se-
lected animal, induced by injecting the L1′ samples in order of in-
creasing concentration, starting with the lowest lipid concentration of
0.17 mg/kg and finishing with the highest one of 1.5 mg/kg. The PAP
always reached the same level. Changes in PAP monitored in another
animal are shown in the lower panel in Fig. 5. When the highest
phospholipid concentration was injected first, partial tachyphylaxis was
observed.
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Fig. 4. Complement activation through C3 protein consumption relative to saline in
porcine sera from six different animals incubated for a period of 40 min at a temperature
of 37 °C with saline and nitroglycerin (NTG), liposomes containing low (L1a, L2a, L3a)
and high (L1, L2, L3) lipid contents, Doxil, Abelcet, and zymosan. The data are shown as
mean values, including standard deviation among animals. Each symbol (triangle, square,
circle, star, cross, rhombus) represents data from one porcine serum. The values were
adjusted to liposome concentrations of 2 and 20 mg/mL, respectively. For the statistical
analysis, zymosan was excluded.
Table 3
Relative maximal changes in pulmonary arterial pressure. Bolus injections were separated
by at least 30-minute recovery periods. Lipid concentrations correspond to the amounts of
Pad-PC-Pad per kg (of pig). The sequence of liposomal injection is given in Supplementary
information (Table S2).
Pig ID L1′
0.5 mg/kg
1/3 × L1′
0.17 mg/kg
3 × L1′
1.5 mg/kg
L2′
0.5 mg/kg
L3′
0.5 mg/kg
PAP (%)
1 14.9 17.7 16.9 4.7 3.5
2 NA 3.5 30.4 8.1 0.0
3 1.9 NA 75.9 2.9 0.0
4 0.0 NA 19.4 8.5 1.5
5 6.3 NA 7.2 NA 4.2
6 6.0 4.8 32.7 1.7 10.1
Mean ± SD 5.8 ± 5.7 8.7 ± 7.9 30.4 ± 24.2 5.2 ± 3.0 3.2 ± 3.8
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3.3.4. Changes in systemic arterial pressure (SAP)
The extrema of the systemic arterial pressure measurements are
listed in Table 4. Contrary to the consistent rise in PAP, SAP showed an
immediate increase or decrease of up to 10% for the 0.1 mg/kg zy-
mosan injection, with the type of reaction depending on the individual
pig. The injection of 70 μg nitroglycerin caused a maximal decrease of
10% in SAP level. The injection of sample L1′ with 3 × HTD resulted in
a significant change in SAP, albeit only for Pig 3.
4. Discussion
Liposome preparation through the extrusion technique is one of the
common methods used to generate uniform liposome suspensions [37].
The mean sizes of the liposomes, being 20% to 70% larger than the
smallest membrane pore size of the filters used, agrees with previous
findings [46]. The liposomes of L2 and L3 exhibit a mean size that re-
flects their stiffness and degree of faceting. These liposomes were ex-
truded above the membrane main phase transition temperature to fa-
cilitate sizing. Nonetheless, parts of the rather stiff membranes of L2
and L3 passed the extrusion filter pores without being sheared, possibly
by adopting an orientation along the flow direction.
The ζ potential measurements characterize liposome surfaces and
the stability of suspensions, both of which are essential for the efficacy
of drug delivery [47]. It has been reported that the presence of
PEGylated lipids affects ζ-potential, which depends on PEG size and
anchor [27,48]. Our results show ζ-potential values close to zero, re-
gardless of PEGylation (Table 2). This behavior can be explained by
Pad-PC-Pad resulting in a neutral, zwitter-ionic amphiphile (Fig. 2, (1)).
The addition of negatively charged DSPE-PEG2000 causes the expected
marginal decrease in the ζ-potential, as the comparison between L1 and
L3 indicates. Encapsulated nitroglycerin has a detectable impact, be-
cause the liposomes prepared in saline (L2) show a ζ-potential which is
more than twice as high as the value of the formulations with ni-
troglycerin, i.e. L1 and L3.
Due to its simplicity, the passive loading of a drug into a liposome
via thin lipid film hydration and freeze-thaw steps is widely used. The
presence of a PEG network inside and outside of the liposome mem-
brane in the formulations L1 and L2 was solely chosen to prevent the
formation of aggregates, which increase the immune system response
[42]. Furthermore, the addition of PEGylated lipids seemed to be
beneficial to nitroglycerin retention and suggests a noncovalent inter-
action between the two molecules.
A semi-quantitative ESI-MS assay, carried out for the liposomal
formulation L1 and L3, showed a high loading of 27% to 49% ni-
troglycerin into Pad-PC-Pad liposomes, respectively. The passive
loading of nitroglycerin is higher than expected from literature data of
passive loading of other drug molecules [49], possibly because of the
low nitroglycerin molecular weight being 227.1 Da.
The present study identified the pathway, through which Pad-PC-
Pad-based liposomes can trigger the complement system. Although the
in vitro results of the immunoassay in human sera clearly indicate no
activation of the lectin pathway, the result has to be treated with care,
because for the lectin pathway test the sample containing Abelcet was
unavailable. The classical pathway, however, can definitely be ruled
out, as zymosan exhibited the expected rise. The predominant role of
the alternative pathway with respect to its classical and lectin coun-
terparts in the presence of PEGylated lipids (L1 and L2 vs. L3) agrees
with information available in the literature [27,48].
Samples containing Abelcet activated the complement system via
the alternative pathway stronger than Doxil and Pad-PC-Pad-based li-
posomes at both high and low phospholipid contents. This enhanced
complement activation is possibly associated with the micrometer size
of the lipid complexes loaded with the amphotericin B drug. A previous
communication [23] reported that larger liposomes increase the risk of
severe immune reactions.
It is not surprising that Pad-PC-Pad-based liposome suspensions L1a,
L2a, and L3a show a SC5b-9 level similar to the Doxil sample. This
behavior is supported by the fact that these liposomes exhibit a size of
about hundred nanometers. These formulations caused mild comple-
ment activation. In particular, the L1 formulation, comprising Pad-PC-
Pad, PEGylated lipid, and the nitroglycerin payload, could trigger the
immune system. This fact is interpreted as being the result of amplifi-
cation caused by combining PEGylated lipids with nitroglycerin, which
is in agreement with our results. The same behavior is known for Doxil,
as doxorubicin and PEGylated lipids cause a higher response than each
component alone [24]. In addition, it has been reported [23] that the
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Fig. 5. Injection of PEGylated nitroglycerin-loaded Pad-
PC-Pad liposomes in two selected animals. The results for
the first animal are represented using filled black circles
(three diagrams on the upper row) and the ones for the
second animal are given by filled black squares (three
diagrams on the lower row). Each row represents a con-
secutive injection protocol in one animal. The bolus in-
jections were separated by a recovery time of at least
30 min.
Table 4
Relative maximal changes in systemic arterial pressure. Lipid concentrations correspond
to the amounts of Pad-PC-Pad per kg (of pig). The sequence of liposomal injection is given
in Supplementary information (Table S2).
Pig ID L1
0.5 mg/kg
1/3 × L1′
0.17 mg/kg
3 × L1′
1.5 mg/kg
L2′
0.5 mg/kg
L3′
0.5 mg/kg
SAP (%)
1 0.0 0.8 9.2 4.9 1.0
2 NA −0.4 0.4 2.1 1.5
3 0.0 NA 23.5 0.7 3.5
4 0.0 NA 7.6 2.6 3.3
5 3.6 NA 7.4 NA 2.0
6 1.7 −0.2 5.7 4.9 4.0
Mean ± SD 1.1 ± 1.6 0.1 ± 0.6 9.0 ± 7.7 3.0 ± 1.8 2.6 ± 1.2
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presence of drugs in the liposome's surface and in the medium sur-
rounding the liposomes could increase complement activation.
A previous in vitro study on Pad-PC-Pad liposomes, where the inner
cavity was loaded with phosphate-buffered saline, showed negligible
complement activation [42]. The nitroglycerin-loaded Pad-PC-Pad li-
posomes (L1a, L2a, and L3a) yielded a SC5b-9 level, well comparable to
the FDA-approved Doxil, for all tested formulations. Furthermore, C3
protein consumption measured in the sample containing Doxil was
comparable to the formulations L1, L2, and L3, a fact explained by the
higher sensitivity of the immune system in the porcine model with re-
spect to humans.
In the animal experiments, the administration of drug-free (L2′) and
nitroglycerin-loaded (L1′ and L3′) liposomes with dosage up to
3 × HTD highlighted no significant changes in the monitored para-
meters, a result which agrees with previous data from liposomes of the
same composition containing phosphate-buffered saline [42].
In addition to the complement activation by L1 formulation, which
can be interpreted as being the result of an amplification caused by
combining PEGylated lipids with nitroglycerin, the non-faceted shape
of the liposomes has to be considered [13,20]. The cryo-TEM micro-
graphs show that the liposomes prepared with or without the addition
of PEGylated lipid and nitroglycerin payload do not only exhibit a size
distribution but significantly differ in shape. As the curvature is size-
and shape-dependent, it is suitable to characterize the liposome's ani-
sotropy by the eccentricity – an approach, which accounts for the recent
interpretation on adverse injection reactions to disk-like and spherical
nanoparticles through shape modification [20].
According to the cryo-TEM images, the L3 formulation, where the
highest eccentricity was found (cf. Table 2), caused the lowest com-
plement activation. On the contrary, the L1 formulation comprising
Pad-PC-Pad, PEGylated lipids, and the nitroglycerin payload with zero-
eccentricity triggered a mild complement activation. The formulation
L2 comprising Pad-PC-Pad, PEGylated lipids and loaded with saline
showed eccentricity and complement activation values between the
formulations L1 and L3. Therefore, the shape could be a key parameter
regulating the acute adverse reactions.
Although the identity of the proteins and receptors, that cause the
adverse reactions, remains unknown [20], one may speculate that the
angles offered to the protein adsorption by the non-spherical liposomes
gain access to the underlying phenomena, as found for nanopyramids
influencing inflammatory reactions more than a decade ago [50,51].
Hence, the presence of hydroxyapatite crystallites in bone and the ad-
vantage of nanometer-scale roughness on lead-bearing implants is un-
derstood. In this context, studies on the three-dimensional structure of
Pad-PC-Pad liposomes will follow as a prerequisite for a detailed un-
derstanding of acute adverse reactions.
One limitation of the Pad-PC-Pad liposomes for applications inside
the human body lies in the main phase transition, which is very close to
body temperature. Above 37 °C, the Pad-PC-Pad liposomes release 5(6)-
carboxyfluorescein completely [11]. Consequently, for clinical use, one
should search for a slightly more stable mechano-responsive container
than the proposed Pad-PC-Pad liposomes.
5. Conclusion
Nanometer-sized Pad-PC-Pad liposomes with a concentration of
20 mg/mL initiate the complement cascade via the alternative pathway,
concluded from an increase in the level of Bb protein. This finding is
confirmed by significant differences with respect to saline in the final stage
of complement activation, represented by the SC5b-9 concentration, which
has been detected as significantly higher than for saline in the final stage of
complement activation. Reducing the lipid content of Pad-PC-Pad to 2 mg/
mL, the complement activation was negligible, a result derived from the in
vitro experiments with human and porcine sera as well as an animal study.
Therefore, the liposomes developed in this context are promising me-
chano-responsive container candidates for targeted drug delivery.
Despite the progress in understanding complex processes involving
the immune system defenders, the shape of the particles may play a
basic role in triggering an immune reaction. To this end, the structure of
the liposomes should be better characterized and optimized towards
slightly higher transition temperatures.
Future efforts will focus on the release kinetics of these mechano-
responsive liposomes of 100 nm diameter for a detailed comparison
with currently used non-encapsulated administration methods of ni-
troglycerin in emergency situations.
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